Table 2.
Model | Hazard ratio (95% CI) | p value |
---|---|---|
All evaluable patients (n = 1440) | 0.5 | |
Patients enrolled after June 2015 (n = 431) | 1.18 (0.76–1.86) | 0.5 |
Meta-analysis combining results from before and after cluster randomization began in June 2012 (n = 1440) | 1.03 (0.94–1.13) | 0.8 |
Model adjusted for PSA, biopsy grade group, and clinical stage (n = 1339) | 0.95 (0.84–1.07) | 0.4 |
CI = confidence interval; PLND = pelvic lymph node dissection; PSA = prostate-specific antigen.